Wanbury Ltd

Stage 4 · Declining · week 2

As of 16 Oct 2026, Wanbury is in Stage 4 — declining, a downtrend, in week 2 (since 5 Oct 2026). It closed at ₹192, 44.2% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. More about the company

₹192.4
+3.25% today
₹673 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is WANBURY early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-44.2%
₹163.3 lo₹344.8 hi
44.2% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 2
1w13w26w
Week 2 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-23.8%
200 DMA: ₹252.4 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.84x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -9.8% vs MA50 -15.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-13.6%
3M
-42.1%
6M
-27.6%
YTD
-17.4%
1Y
-22.5%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 66 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 56 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 34w
S2 34w
S3 14w
S4 14w
S2 19w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 1w → S2 34w → S3 5w → S2 34w → S3 5w → S4 5w → S1 4w → S2 11w → S3 14w → S4 14w → S1 8w → S2 19w → S3 5w → S4 2w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Pullback Hunter
Latest: 2026-07-31
Prop Scan
Latest: 2026-07-31
60 appearances in last 60 days. First seen: 2026-06-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S4
Wk 2 · Vol 0.84x
2026-10-15S4
Wk 2 · Vol 0.53x
2026-10-14S4
Wk 2 · Vol 0.35x
2026-10-13S4
Wk 2 · Vol 0.36x
2026-10-12S4
Wk 2 · Vol 0.69x
2026-10-09S4
Wk 1 · Vol 1.06x
2026-10-08S4
Wk 1 · Vol 1.09x
2026-10-07S4
Wk 1 · Vol 1.41x
2026-10-06S4
Wk 1 · Vol 3.70x
2026-10-05S43→4
Wk 1 · Vol 1.72x
2026-10-01S3
Wk 6 · Vol 1.87x
2026-09-30S3
Wk 5 · Vol 3.42x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹233.6
200 DMA
₹252.4
52W High
₹344.8
52W Low
₹163.3
5D Low
₹186.3
Resistance levels (recent highs)
20d High
₹233.1
60d High
₹331.9
120d High
₹344.8
250d High
₹344.8
Next resistance
+21.2%
to 20d High
Ask the Market AI about WANBURYAsk →
P/E (TTM)
15.7
Forward —
About this companyHealth Care· Pharmaceuticals

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.